Phase II trial of preoperative chemotherapy for breast cancer: Japan Breast Cancer Research Network (JBCRN)-02 trial

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1483-1487

  Iwase, S ^a   Yamamoto, Daigo ^b   Kuroda, Y ^a   Kawaguchi, T ^c   Kitamura, K ^d   Odagiri, H ^e   Teramoto, S ^d   Akazawa, K ^f   Nagumo, Y ^g  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^d KYUSHU CENTRAL HOSPITAL   (Japan)

^e HIROSAKI UNIVERSITY   (Japan)

^f NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^g Nagumo Clinic   (Japan)

Author keywords

Adjuvant chemotherapy; Breast cancer; Sequential therapy

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PACLITAXEL; RANITIDINE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CANCER SURGERY; CLINICAL ARTICLE; DIARRHEA; DISEASE FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; HAIR LOSS; HAND FOOT SYNDROME; HUMAN; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SENSORY NEUROPATHY; STOMATITIS; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79956145111     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kuerer HM, Newman LA, Smith TL Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN and Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxombicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469, 1999. (Pubitemid 29075229)
2. Kaufmann M, Hortobagyi GN, Goldhirsch A Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M and von Minckwitz G: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24: 1940-1949, 2006.
3. Bear HD, Anderson S, Smith RE, Geyer CE Jr., Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL and Wolmark N: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24: 2019-27, 2006. (Pubitemid 46622110)
4. Abrial SC, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, Mery-Mignard D, Bleuse JP, Dauplat J, Curé H and Chollet P: High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 94: 255-263, 2005. (Pubitemid 41677630)
5. Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y and Takatsuka Y: Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease-free survival. Breast Cancer Res Treat 770: 531-539, 2008. (Pubitemid 351962591)
6. Kinoshita T: Preoperative therapy: recent findings. Breast Cancer 23: 2010.
7. Iwase S, Yamamoto, D, Kitamura K, Odagiri H, Teramoto S, Ohtani S, Doi T, Kinebuchi K, Kuroda Y and Nagumo Y: Phase II study of AC (doxorubicin and cyclophosphamide) followed by weekly paclitaxel as neoadjuvant chemotherapy in operable patients with primary breast cancer. J Clin Oncol 27: (suppl) abstr. e11587, 2009.
8. Nishimura R, Osako T, Okumura Y, Hayashi M and Arima N: Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer 77: 269-275, 2010.
9. von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A and Kaufmann M: Clinical response after two cycles compared to HER2, Ki-67, p53, and BCL-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10: R30, 2008.
10. Nishimura R and Arima N: Is triple negative a prognostic factor in breast cancer? Breast Cancer 15: 303-308, 2008.
11. Nishimura R, Okumura Y and Arima N: Trastuzumab: monotherapy versus combination therapy for treating recurrent breast cancer - time to progression and survival. Breast Cancer 75: 57-64, 2008.
12. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U and Bruzzi P: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100: 14-20, 2008. (Pubitemid 351767337)
13. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN and Pusztai L: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275-1281, 2008.
14. Di Leo A, Tanner M, Desmedt C, Paesmans M, Cardoso F, Durbecq V, Chan S, Perren T, Aapro M, Sotiriou C, Piccart MJ, Larsimont D and Isola J; TAX 303 Translational Study Team: p53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol 18: 997-1003, 2007.
15. Sánchez-Muñoz A, García-Tapiador AM, Martínez-Ortega E, Dueñas-García R, Jaén-Morago A, Ortega-Granados AL, Fernández-Navarro M, de la Torre-Cabrera C, Dueñas B, Rueda AI, Morales F, Ramírez-Torosa C, Martín-Salvago MD and Sánchez-Rovira P: Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol 10: 646-653, 2008.
16. Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN and Symmans WF: Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 79: 2020-2025, 2008.
17. Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI and Messersmith H: Adjuvant/neoadjuvant trastuzumab therapy in women with HER2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 34: 539-557, 2008.